ArticleJournal of molecular histology2026
Salidroside attenuates diabetic retinopathy by upregulating miR-142-3p to target TRAF6.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the role and molecular mechanisms of salidroside (SAL) in retinal vascular dysfunction under diabetic conditions. Human retinal microvascular endothelial cells (HRMECs) were cultured in a 30 mM high glucose (HG) medium to mimic diabetic conditions. Cell proliferation, migration, and angiogenesis were assessed by CCK-8, Transwell, and Matrigel tube formation assay, respectively. Tight junction-associated proteins ZO-1, occludin, and claudin-5 were detected by Western blot. The targeting relationship between miR-142-3p and TRAF6 was verified by bioinformatics analysis and dual-luciferase reporter gene assay. Retinal tissues from a streptozotocin (STZ)-induced diabetic rat model were examined by hematoxylin and eosin (HE) staining. SAL inhibited HG-induced proliferation, migration, and angiogenesis of HRMECs and promoted the expression of ZO-1, occludin, and claudin-5. SAL upregulated miR-142-3p expression, and miR-142-3p targeted TRAF6 to negatively regulate its expression. The inhibitory effects of SAL on HRMECs were reduced by lowering miR-142-3p or raising TRAF6 levels. SAL ameliorated retinopathy in diabetic rats. SAL attenuates diabetic retinal vascular dysfunction by upregulating miR-142-3p and downregulating TRAF6.
Indexed as
Identifiers
42249147What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.